| Co-Investigator(Kenkyū-buntansha) |
HIGASHI Tatsuya 滋賀県立成人病センター, 研究所, 総括研究員 (50324629)
KAGAWA Shinya 滋賀県立成人病センター, 研究所, 主任研究員 (10393191)
KAWAI Keiichi 金沢大学, 大学院医学研究科, 教授 (30204663)
MIZUMA Hiroshi 理化学研究所, ライフサイエンス技術基盤センター, 研究員 (00382200)
NAGAMACHI Shigeki 宮崎大学, 医学部, 准教授 (40180517)
|
|---|
| Budget Amount *help |
¥22,100,000 (Direct Cost: ¥17,000,000、Indirect Cost: ¥5,100,000)
Fiscal Year 2014: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2013: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2012: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
Fiscal Year 2011: ¥8,190,000 (Direct Cost: ¥6,300,000、Indirect Cost: ¥1,890,000)
|
|---|
| Outline of Final Research Achievements |
Epigenetic modifications mediated by histone deacetylases (HDACs) play important roles in the mechanisms of different neurologic diseases and HDACIs have shown promise in therapy. However, pharmacodynamic profiles of many HDACIs in the brain remain largely unknown due to the lack of validated methods for noninvasive imaging of HDAC expression-activity. In this study, radiosynthesis of novel PET tracer of [18F]FAHA, a novel HDAC substrate and assessment the efficacy of [18F]FAHA PET imaging was performed. And also, [18F]fluoroacetate, the major radio-metabolite of [18F]FAHA was focused on for brain imaging using animal study. PET imaging with [18F]FAHA reflects the level of expression-activity of HDAC class IIa enzymes. The results suggest that the HDAC inhibitor may have efficacy, especially in the acute phase of the ischemic stroke and that the [18F]FAHA-PET and [18F]fluoroacetate-PET imaging are quite useful for providing a new therapeutic strategy in ischemic stroke.
|
